🎉 M&A multiples are live!
Check it out!

ProKidney Valuation Multiples

Discover revenue and EBITDA valuation multiples for ProKidney and similar public comparables like Pharming, Julphar, and Benevolent AI.

ProKidney Overview

About ProKidney

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.


Founded

2021

HQ

United States of America
Employees

204

Website

prokidney.com

Financials

LTM Revenue $0.1M

LTM EBITDA -$177M

EV

-$259M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

ProKidney Financials

ProKidney has a last 12-month revenue of $0.1M and a last 12-month EBITDA of -$177M.

In the most recent fiscal year, ProKidney achieved revenue of $0.1M and an EBITDA of -$158M.

ProKidney expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See ProKidney valuation multiples based on analyst estimates

ProKidney P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $0.1M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$126M -$158M XXX XXX XXX
EBITDA Margin -Infinity% -208542% XXX XXX XXX
Net Profit -$108M -$35.5M XXX XXX XXX
Net Margin -Infinity% -46668% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

ProKidney Stock Performance

As of April 15, 2025, ProKidney's stock price is $1.

ProKidney has current market cap of $95.9M, and EV of -$259M.

See ProKidney trading valuation data

ProKidney Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$259M $95.9M XXX XXX XXX XXX $-0.61

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

ProKidney Valuation Multiples

As of April 15, 2025, ProKidney has market cap of $95.9M and EV of -$259M.

ProKidney's trades at -4787.8x LTM EV/Revenue multiple, and 1.5x LTM EBITDA.

Analysts estimate ProKidney's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for ProKidney and 10K+ public comps

ProKidney Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$259M XXX XXX XXX
EV/Revenue -3410.5x XXX XXX XXX
EV/EBITDA 1.6x XXX XXX XXX
P/E -1.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ProKidney Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

ProKidney Valuation Multiples

ProKidney's NTM/LTM revenue growth is -100%

ProKidney's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged $0.9M for the same period.

Over next 12 months, ProKidney's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate ProKidney's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for ProKidney and other 10K+ public comps

ProKidney Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -208542% XXX XXX XXX XXX
EBITDA Growth 26% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0K XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 73795% XXX XXX XXX XXX
R&D Expenses to Revenue 167984% XXX XXX XXX XXX
Opex to Revenue 241779% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

ProKidney Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

ProKidney M&A and Investment Activity

ProKidney acquired  XXX companies to date.

Last acquisition by ProKidney was  XXXXXXXX, XXXXX XXXXX XXXXXX . ProKidney acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by ProKidney

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About ProKidney

When was ProKidney founded? ProKidney was founded in 2021.
Where is ProKidney headquartered? ProKidney is headquartered in United States of America.
How many employees does ProKidney have? As of today, ProKidney has 204 employees.
Who is the CEO of ProKidney? ProKidney's CEO is Dr. Bruce Culleton, M.D..
Is ProKidney publicy listed? Yes, ProKidney is a public company listed on NAS.
What is the stock symbol of ProKidney? ProKidney trades under PROK ticker.
When did ProKidney go public? ProKidney went public in 2022.
Who are competitors of ProKidney? Similar companies to ProKidney include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of ProKidney? ProKidney's current market cap is $95.9M
What is the current revenue of ProKidney? ProKidney's last 12-month revenue is $0.1M.
What is the current EBITDA of ProKidney? ProKidney's last 12-month EBITDA is -$177M.
What is the current EV/Revenue multiple of ProKidney? Current revenue multiple of ProKidney is -4787.8x.
What is the current EV/EBITDA multiple of ProKidney? Current EBITDA multiple of ProKidney is 1.5x.
Is ProKidney profitable? Yes, ProKidney is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.